<DOC>
	<DOCNO>NCT00499499</DOCNO>
	<brief_summary>The purpose study investigate E7107 patient solid tumor . This open label , dose-escalation study E7107 . The maximum tolerated dose ( MTD ) single agent establish determine occurrence dose limit toxicity first three week therapy ( Cycle 1 ) . Patients study treated multiple dose level , start 0.6 mg/m^2 . Patients receive E7107 30-minute intravenous infusion Days 1 8 every 21 Days .</brief_summary>
	<brief_title>A Dose Escalation Study E7107 Administered Intravenously Days 1 8 Every 21 Days Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA : Patients must meet inclusion criterion outline order eligible participate study . 1 . Patients histologically and/or cytologically confirm solid tumor progress receive approve therapy disease effective therapy available . 2 . Surgery radiotherapy must complete least four week prior study entry , prior chemotherapy anticancer therapy , exclude bisphosphonates steady dose level , must discontinue 2 3 week previously . All acute toxicity relate treatment must resolve . 3 . Aged ≥ 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 1 . 5 . Written inform consent prior study specific screening procedure , include mandatory consent provide blood sample specifically pharmacogenomic analysis , understand patient may withdraw consent time without prejudice . Tumor biopsy pharmacogenomic ( PG ) analysis voluntary . 6 . Willing able comply protocol duration study . 7 . Anticipated life expectancy &gt; three month . EXCLUSION CRITERIA : Patients follow characteristic eligible study . 1 . Symptomatic progressive brain tumor brain leptomeningeal ( CNS ) metastases require clinical intervention , except complete local therapy discontinue use corticosteroid indication least two week start treatment E7107 . 2 . Any following laboratory parameter : 1. hemoglobin &lt; 9 g/dL ( 5.6 mM ) 2. neutrophil &lt; 1.5 x 10^9/L 3. platelet &lt; 100 x 10^9/L 4. serum bilirubin &gt; 25 μM ( 1.5 mg/dL ) 5. liver function test ( define AST ALT ) value &gt; 3 x ULN ( 5 x ULN liver metastasis present ) 6. serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 40 mL/min . 3 . Positive history HIV , active hepatitis B active hepatitis C severe/uncontrolled intercurrent illness infection . 4 . Clinically significant cardiac impairment unstable ischemic heart disease ( great Class II accord New York Heart Association ( NYHA ) classification ) include myocardial infarction within six month study start . 5 . Bleeding thrombotic disorder , use therapeutic dosage anticoagulant 6 . History alcoholism , drug addiction , psychiatric psychological condition , opinion Investigator , would impair study compliance . 7 . Women pregnant breastfeeding . Women childbearing potential either positive serum pregnancy test screening , positive urine pregnancy test begin cycle , pregnancy test . Women childbearing potential unless use two form contraception , one must barrier method . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . 8 . Fertile men fertile woman willing use contraception , fertile men fertile woman partner willing use contraception 9 . Patients mark screen baseline prolongation QT/QTc interval use Fridericia formula ( ie , repeated demonstration QTc interval &gt; 450 msec ) ; history additional risk factor Torsade de Pointe ( e.g. , heart failure , hypokalaemia , history Long QT Syndrome ) . 10 . Patients radiation &gt; = 25 % bone marrow ( e.g. , pelvic radiation ) . 11 . Patients history previous Grade 2 high hypersensitivity pladienolide B derivative excipients formulation 12 . Patients significant comorbid disease condition , Investigator 's opinion would exclude patient study 13 . Patients receive organ allograft ie , require immunosuppressive therapy 14 . Beginning two week prior dose , patient allow take drug strong CYP inhibitor ( include grapefruit juice herbal supplement ) inducer ( include herbal supplement ) , metabolize cytochrome P ( CYPs ) know narrow therapeutic window . 15 . After MTD reach : Second malignancy within past 5 year , except carcinoma situ cervix , basal cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>solid tumor</keyword>
</DOC>